Intriguingly, preliminary data from our group, under approved IRB protocols, has demonstrated an increased level of survivin in the plasma samples of MASH-related HCC patients compared to MASH patients and normal subjects, which correlated positively with the clinicopathological parameters of the patients. The gene discussed is BIRC5; the disease is hepatocellular carcinoma.